Skip to content

Epidermal Cells Delivery and Acute Burns

A Randomized Trial Comparing Recell® Autologous Epidermal Cells Harvesting Kits Versus Classic Skin Grafts for the Treatment of Acute Burn in Adults and Children

Status
Terminated
Phases
Phase 3
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00774033
Acronym
ENSEM
Enrollment
51
Registered
2008-10-16
Start date
2008-12-31
Completion date
2012-05-31
Last updated
2012-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Burn

Keywords

Keratinocytes, Cell spray, Deep partial thickness burns, Full thickness burns

Brief summary

The aim of the study is to compare results obtained with epidermal cell spray and classic skin grafting for epidermal replacement in acute burns

Detailed description

Comparing the impact in terms of cicatrisation duration and costs between 2 treatments of deep 2nd and 3rd degree burns. Determine if the costs of the innovating treatment RECELL®, a priori more expensive, are counterbalanced by a shorter cicatrisation duration and an improved evolution versus a conventional strategy. Give an information about efficiency improvement of RECELL® with additional costs

Interventions

DEVICEautologous epidermal cells harvesting kits

autologous epidermal cells harvesting kits used for the treatment of acute burn

PROCEDUREclassic skin grafts

classic skin grafts used for the treatment of acute burn

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Thermal burns requiring surgical debridement * Area involved \< 1260cm²

Exclusion criteria

* local or systemic infection * conditions that would interfere with wound healing (diabetes, hypertension, inflammatory diseases treated by corticoids) * hypersensitivity to trypsin

Design outcomes

Primary

MeasureTime frame
80% epithelialisation (recipient + owner sites) at one week. Percent epithelialisation at 1, 2 and 6 weeks.at 1, 2 and 6 weeks

Secondary

MeasureTime frame
Medical costs at complete epithelialisationAt 6, 12 and 18 months
Post-operative painAt 6 weeks
Medical assessment of scar qualityat 6 weeks and 6, 12, 18 months
Patient self assessment of scarAt 6, 12 and 18 months

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026